Conclusions : C and esartan is superior to losartan in reducing blood pressure .
C and esartan also causes fewer serious adverse events than losartan
Background : C and esartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker ( ARB ) .
Several clinical trials have compared c and esartan with losartan in the management of essential hypertension .
However , systematic assessment of efficacy and safety between c and esartan and losartan is still lacking .
Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
This r and omized , double-blind study compared the antihypertensive effect , safety and tolerability of a c and esartan cilexetil/hydrochlorothiazide ( c and esartan/HCT ; 16/12.5 mg ) combination tablet with that of a losartan/HCT ( 50/12.5 mg ) combination tablet in patients with mild-to-moderate primary hypertension insufficiently controlled on previous monotherapy . Men and women , aged 20 - 80 years , with a sitting diastolic blood pressure ( DBP ) > or = 90 and < or = 110 mmHg and sitting systolic blood pressure ( SBP ) < or = 200 mmHg during treatment with any kind of antihypertensive monotherapy for at least 4 weeks were r and omized to c and esartan/HCT or losartan/HCT once daily for 12 weeks . All BP measurements were performed 24 h after previous dose . Mean values and st and ard deviations ( SD ) or confidence intervals ( CI ) are given . A total of 340 patients were enrolled , of whom 299 ( 144 women and 155 men , mean age 59.5 [ 10.5 ] years ) were r and omized to c and esartan/HCT ( n = 151 ) or losartan/HCT ( n = 148 ) . BPs at r and omization were 159.5 (15.4)/98.4 (5.8)mmHg and 160.5 (16.1)/98.5 (5.4)mmHg , respectively . There was a greater reduction in BP with c and esartan/HCT than with losartan/HCT : DBP -10.4 ( -11.8 ; -8.9 ) vs -7.8 ( -9.3 ; -6.3 ) mmHg , difference between treatments -2.6 ( -4.7 ; -0.5 ) mmHg ( p = 0.016 ) ; SBP -19.4 ( -22.1 ; -16.7 ) vs - 13.7 ( -16.5 ; - 10.9 ) mmHg , difference between treatments -5.7 ( -9.6 ; -1.8 ) mmHg ( p = 0.004 ) . The proportion of patients achieving a DBP < or = 90 mmHg was greater in the c and esartan/HCT group : 60.9 ( 53.1 ; 68.7 ) vs 49.3 ( 41.3 ; 57.4)% ( p = 0.044 ) . There were 12 withdrawals in the c and esartan/HCT group , of which 8 were due to adverse events , and 17 and 12 , respectively in the losartan/HCT group . We conclude that the combination of c and esartan and HCT reduces BP effectively and is well tolerated . BP was normalized in 61 % of these patients who had insufficient response to previous monotherapy . The reduction in BP and the proportion of patients with normalized BP were greater with the c and esartan/HCT 16/12.5 mg combination than with the losartan/ HCT 50/12.5 mg combination
Conclusions : C and esartan is superior to losartan in reducing blood pressure .
C and esartan also causes fewer serious adverse events than losartan
Background : C and esartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker ( ARB ) .
Several clinical trials have compared c and esartan with losartan in the management of essential hypertension .
However , systematic assessment of efficacy and safety between c and esartan and losartan is still lacking .